Efficacy and Safety of Erlotinib in 1242 East/South-East Asian Patients with Advanced Non-small Cell Lung Cancer
Publication in refereed journal

Times Cited
Web of Science33WOS source URL (as at 29/11/2020) Click here for the latest count
Altmetrics Information

Other information
AbstractIntroduction: Erlotinib is an epidermal growth factor receptor tyrosine kinase inhibitor that significantly increases survival for patients with previously treated advanced non-small cell lung cancer. Epidermal growth factor receptor tyrosine kinase inhibitors have been reported to be particularly effective in Asian patients and may have a distinct safety profile in this population compared with non-Asian patients. We report safety and efficacy data from a subpopulation of East/South-East (E/SE) Asian patients enrolled in a global, open-label, phase IV trial of erlotinib (Tarceva Lung Cancer Survival Treatment study).
All Author(s) ListMok T, Wu YL, Au JSK, Zhou CC, Zhang L, Perng RP, Park K
Journal nameJournal of Thoracic Oncology
Volume Number5
Issue Number10
PublisherLippincott, Williams & Wilkins
Pages1609 - 1615
LanguagesEnglish-United Kingdom
KeywordsAsia; Erlotinib; NSCLC; Phase IV; TRUST
Web of Science Subject CategoriesOncology; ONCOLOGY; Respiratory System; RESPIRATORY SYSTEM

Last updated on 2020-29-11 at 23:54